Novartis takes another stride toward Alexion's turf with PhIII PNH win

Amber Tong

Looking to break into a rare disease field that AstraZeneca subsidiary Alexion has dominated for years, Novartis says its oral drug bested anti-C5 therapies in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis takes another stride toward Alexion's turf with PhIII PNH win

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists ...

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

A VC-backed genetic testing startup to 'consider' making an offer to buy 23andMe

Biotech VC firm outlines plans for $100M fund

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Breaking down silos with a new quantitative approach to drug development

No­var­tis takes an­oth­er stride to­ward Alex­ion's turf with PhI­II PNH win

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Novartis takes another stride toward Alexion's turf with PhIII PNH win